Scribd
Upload
6 views1 page

Citation 336110603

The document discusses the role of selegiline, a selective monoamine oxidase B (MAO-B) inhibitor, in treating Parkinson's disease, highlighting its innovative pharmacological properties and the historical context of its development. It outlines the initial research that established selegiline's effectiveness in improving symptoms when used with levodopa, despite the challenges posed by earlier non-selective MAO inhibitors. Recent studies suggest that selegiline may offer neuroprotective benefits and a potential disease-modifying effect in Parkinson's treatment.

Uploaded by

xebopar290
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as TXT, PDF, TXT or read online on Scribd
6 views1 page

Citation 336110603

The document discusses the role of selegiline, a selective monoamine oxidase B (MAO-B) inhibitor, in treating Parkinson's disease, highlighting its innovative pharmacological properties and the historical context of its development. It outlines the initial research that established selegiline's effectiveness in improving symptoms when used with levodopa, despite the challenges posed by earlier non-selective MAO inhibitors. Recent studies suggest that selegiline may offer neuroprotective benefits and a potential disease-modifying effect in Parkinson's treatment.

Uploaded by

xebopar290
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as TXT, PDF, TXT or read online on Scribd
You are on page 1/ 1

Vecsei, László & Youdim, Moussa & Riederer, Peter & Szökö, Eva. (2020).

Selegiline:
a molecule with innovative potential. Journal of Neural Transmission. 127.
10.1007/s00702-019-02082-0. Monoamine oxidase B (MAO-B) inhibitors have an
established role in the treatment of Parkinson’s disease as monotherapy or adjuvant
to levodopa. Two major recognitions were required for their introduction into this
therapeutic field. The first was the elucidation of the novel pharmacological
properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the
original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect
in parkinsonian patients with on–off phases. In the 1960s, MAO inhibitors were
mainly studied as potential antidepressants, but Birkmayer found that combined use
of levodopa and various MAO inhibitors improved akinesia in Parkinson’s disease.
However, the serious side effects of the first non-selective MAO inhibitors
prevented their further use. Later studies demonstrated that MAO-B, mainly located
in glial cells, is important for dopamine metabolism in the brain. Recently, cell
and molecular studies revealed interesting properties of selegiline opening new
possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-
B inhibitors.

You might also like